Open Access

The clearance effect of bovine anti-Helicobacter pylori antibody-containing milk in O blood group Helicobacter pylori-infected patients: a randomized double-blind clinical trial

  • Dailun Hu1,
  • Feng Zhang3,
  • Jikun Zhou2,
  • Baohong Xu2,
  • Hongying Zhang2,
  • Huiqin Qiang5,
  • Shuguang Ren4,
  • Baoen Shan4,
  • Changfu Yin1,
  • Zhitao Zhang1,
  • Xian Wang2,
  • Chuan Zhao2Email author and
  • Zhongli Shi1Email author
Journal of Translational Medicine201513:205

https://doi.org/10.1186/s12967-015-0558-1

Received: 26 March 2015

Accepted: 2 June 2015

Published: 30 June 2015

Abstract

Background

The failure in standard triple therapy has recently increased to high levels in China, primarily because of insufficient patient compliance, antimicrobial resistance, and high costs. Effective prevention and eradication of Helicobacter pylori (H. pylori) by artificial passive immunization with orally administered bovine antibodies in the milk has been demonstrated in many animal studies, but the clinical studies that are available have shown no H. pylori eradication. This study was to evaluate the efficacy and safety of orally administered bovine anti-H. pylori antibodies for the clearance of H. pylori infecting O blood group subpopulations.

Methods

Two local epidemic H. pylori strains that were prevalent locally were screened and then used to immunize dairy cows. After confirmation of the presence of anti-H. pylori polyclonal antibodies in the milk by enzyme-linked immunosorbent assay, the milk was subsequently defatted and processed into sterile milk by pasteurization. This study was designed as a double-blind placebo-controlled randomized clinical trial. Our 61 H. pylori-infected O blood group subjects were assigned to two groups; 31 subjects were treated with bovine milk containing antibodies and 30 subjects with the placebo. The medication-based study was continued for 28 days. Subjects were followed up for 56 days. The effect was assessed by the C-14 urea breath test (UBT). SPSS 17.0 software for Windows was used to analyze the data.

Results

Of the 61 subjects enrolled, 58 completed the protocol. One volunteer in the antibodies group and two volunteers in the control group dropped out. Of the 30 antibody-treated subjects, 13 became UBT negative, whereas none of the 30 of the placebo-treated subjects became UBT negative after the medication. Of 13 UBT negative patients, 3 became positive again at the end of the follow-up. Both intention to treat and per-protocol analysis indicated a significant difference in the clearance rate of infected patients between the groups treated with bovine antibody-containing milk and the placebo (P = 0.001, P < 0.05) and no significant difference in adverse effects (P > 0.05 all).

Conclusions

Bovine antibody-based oral immunotherapy appears to be safe and has a significant clearance effect on intragastric H. pylori that infects O blood group adults.

Trial registration: ChiCTR-TRC-14005212.

Keywords

H. pylori Clearance rate Cow milk Antibodies O blood group Lewis blood group

Background

Helicobacter pylori infection is the main cause of gastritis, gastroduodenal ulcer, gastric adenocarcinoma, and mucosa-associated tissue lymphoma [1]. Indeed, H. pylori was recognized as a category I human carcinogen by the WHO/International Agency for Research on Cancer (WHO/IARC) in 1994 [2]. The eradication of H. pylori is now clearly central to the management of the illnesses described above.

The genotypes of H. pylori are based on two virulent genes: cagA and vacA. Different geographic locations have different H. pylori genotypes [3]. CagA-positive H. pylori is reported to be 60–70% of H. pylori strains isolated from Europe, whereas more than 90% of H. pylori strains are cagA positive in eastern Asian countries [4, 5]. The vacA gene has vacA signal (s) and middle (m) regions, which are divided into s1 or s2 and m1 or m2, respectively. The vacA s1 region is further divided into s1a, s1b, and s1c. The m1 region is further classified into m1a, m1b, and m1c, and the m2 region into m2a and m2b [6, 7]. Different geographic regions have different combination of vacA allele and cagA. These variations in the global distribution of the cagA and vacA genotypes might account for the diversity of reports associating the cagA and vacA genotypes with the clinical outcome from these different regions. The serotypes of H. pylori are based on the different repeating oligosaccharides units of lipopolysacchride (LPS) molecules, whereby six distinct H. pylori serotypes (O1–O6) have been defined [8]. Subsequently, detailed structural studies have shown that the LPSs of H. pylori are unique in that their O-chain region is homologous to mammalian histo-blood group antigens. According to Lewis epitopes present in O-glycans and the terminal ABH structures, O-chain components of H. pylori are divided into type 1 Lea, Leb, Led, Linear B and A determinants; type 2 N-acetyl-lactosamine (LacNAc), Lewisx (Lex), Ley, Sialyl Lex, in monomeric and polymeric forms [9]. Like the genotype, the Lewis epitope of H. pylori has geographic variations. H. pylori strains from Asian population seem to have a higher tendency to produce the type 1 antigens, Lea and Leb, whereas those isolated from North American and European hosts express mainly the type 2 antigens, Lex and Ley. Some of H. pylori attach to the epithelium via BabA, SabA, and probably other adhesins. Epidemiologically, individuals of the O blood group are particularly prone to H. pylori infection because their gastric epithelium highly expresses the Leb antigen, which is the BabA of H. pylori binding sites [10, 11].

The eradication rate after standard triple therapy has declined below 80% in most areas and has many adverse effects [1214]. With the widespread use of antibiotics, the increased resistance to antibiotics and their expensive costs make eradication difficult in China [15]. New therapeutic strategies are needed to solve the problems mentioned above. The approach of passive immunization with orally administered antibodies against H. pylori is likely to constitute one of the new therapeutic strategies [16]. This approach mimics naïve protection in humans and has been shown to be effective in the prevention and treatment of a variety of pathogens, such as Rotavirus, Clostridium difficile, and Campylobacter jejuni [1721]. Many animal studies have shown that bovine antibody-containing milk against H. pylori reduces bacterial load, thus preventing and even eradicating H. pylori infection [2225]. However, the available clinical studies of bovine antibodies in milk have not shown H. pylori eradication [2629]. Few clinical studies have been reported based on screening the local epidemic H. pylori strains according to Lewis blood group structure and the vacA allele to immunize diary cows. This clinical study was therefore performed to evaluate the efficacy and safety of specific anti-H. pylori polyclonal bovine antibodies in milk for the clearance of intragastric Helicobacter infection in O blood group subpopulations.

Methods

Bacterial strains and growth

Two local epidemic strains in Shijiazhuang city were screened by sequencing the vacA allele and CagA gene (Table 1) of a total of 276 H. pylori strains that were isolated and collected between March 2008 and August 2011 from the gastric antrum or corpus of patients who had undergone endoscopy at the Fourth Hospital of Hebei Medical University [30, 31]. The two H. pylori strains were named Hp5162 and Hp4236, and the vacA genotype was respectively s1a/m2 (127/276) and s1a/m1 (87/276), both of which were CagA-positive and isolated from O blood group patients. The phenotype of the Lewis blood-group antigens in the LPS of two H. pylori strains was analyzed by serological studies, by using Lewis blood-group-specific Lea, Leb, Lex, Ley monoclonal antibodies (Santa Cruz Biotechnology Inc, Dallas, TX, USA) on whole cells by enzyme-linked immunosorbent assay (ELISA), respectively, with both indicating the presence of the type-1 Leb epitope on the cell surface [32, 33]. Two H. pylori strains, which were preserved as frozen stocks at −80°C in brain heart infusion media supplemented with 20% glycerol and 10% fetal bovine serum (FBS), were revived and cultured on Columbia Agar medium plates (Oxoid Ltd., Basingstoke, Hampshire, England) supplemented with 10% defibrinated sheep blood, 5 mg/L trimethoprim, 5 mg/L polymixin-B, 5 mg/L amphoteracin-B, and 10 mg/L vancomucin (all antibiotics were purchased from Solarbio, Beijing, China), under micro-aerobic conditions (10% CO2, 85% N2, 5% O2) at 37°C for 3–10 days with 95% humidity. H. pylori bacterial cells were harvested from 9-cm Agar plates with a sterile loop. The H. pylori bacterial cells were washed with sterile 0.9% normal saline three times, suspended in 0.1 mol/L phosphate-buffered saline (PBS) for use as vaccines, and kept at −80°C until required.
Table 1

Oligonucleotide primers used for polymerase chain reaction (PCR), PCR conditions, and product size of vacA alleles and cagA

Genes

Primers

Product size (bp)

Initial denaturation temperature °C (min)

Denaturation temperature °C (min)

Annealing temperature °C (min)

Extension temperature °C (min)

Cycles

Final extension temperature °C (min)

s1a

F:5′-GTCAGCATCACACCGCAAC-3′

190

 

94 (1)

52 (1)

72 (1)

35

72 (5)

R:5′-CTGCTTGAATGCGCCAAAC-3′

s1b

F:5′-AGCGCCATACCGCAAGAG-3′

187

 

94 (1)

52 (1)

72 (1)

35

72 (5)

R:5′-CTGCTTGAATGCGCCAAAC-3′

s2

F: 5′-GCTAACACGCCAAATGATCC-3′

199

 

94 (1)

52 (1)

72 (1)

35

72 (5)

R: 5′-CTGCTTGAATGCGCCAAAC-3′

m1a

F: 5′-GGTCAAAATGCGGTCATGG-3′

290

95 (2)

94 (0.5)

52 (0.5)

72 (0.5)

40

72 (5)

R: 5′-CCATTGGTACCTGTAGAAAC-3′

m1b

F: 5′-GGCCCCAATGCAGTCATGGAT-3′

240–270

95 (2)

94 (0.5)

52 (0.5)

72 (0.5)

40

72 (5)

R: 5′-GCTGTTAGTGCCTAAAGAAGCAT-3′

m2

F: 5′-GGAGCCCCAGGAAACATTG-3′

352

95 (2)

94 (0.5)

52 (0.5)

72 (0.5)

40

72 (5)

R: 5′-CATAACTAGCGCCTTGCAC-3′

cagA

F:5′-TTGACCAACAACCACAAACCGAAG-3′

183

94 (2)

95 (0.5)

50 (0.75)

72 (0.75)

40

72 (5)

R:5′-CTTCCCTTAATTGCGAGATTCC-3′

Detection of vacA alleles and cagA. The vacA and cagA genotyping was performed by PCR by using specific primers, as described in Table 1. PCR was conducted in 25-μL volumes containing 1 × PCR buffer, 1 μL of the DNA template, 0.2 mmol/L dNTP mixes, 6 pmol of each primer, and 0.75 U Taq polymerase (New England Biolabs, Ipswitch, MA, USA). The amplified products were electrophoresed on a 1.5% agarose gel, stained with ethidium bromide, and visualized under ultraviolet illumination.

Immunization of dairy cows

The Animal Care Committee of Hebei Academy of Agriculture and Forestry Sciences approved the immunization protocol. Four pregnant dairy bovines were vaccinated with the mixture of Hp5162 and Hp4236 H. pylori for a total of 8 times, 2 times during the last month before parturition, and 6 times after parturition. Vaccination was performed each time with 6 × 109 cfu H. pylori, by means of intranasal mucosal drip, supramammary lymph node (subcutaneous), and hip muscle administration at four sites (once every 2 weeks). Dairy cows were boosted at about 2-week intervals. The H. pylori suspension was emulsified with an equal volume of Freund’s complete adjuvant for the initial immunization and Freund’s incomplete adjuvant for each of the boosts. Milk and serum samples were collected from each cow before immunization and 50 days after immunization for the detection of antibodies by ELISA.

Detection of antibody by ELISA

Overnight cultures of bacteria were collected by centrifugation (5,000×g, 10 min, 4°C), washed three times with PBS, and repelleted at 10,000×g for 2 min. Total proteins were extracted by using the ProteoPrep® Sample Extraction kit (Sigma-Aldrich Corporation, St. Louis, MO, USA) according to the manufacturer’s instructions. The protein concentration was measured by the Pierce™ BCA Protein Assay kit (Thermo Fisher Scientific Inc, Waltham, MA, USA). Microplates were pretreated with 2.5% glutaraldehyde, and each ELISA plate was coated with 100 µl H. pylori at a concentration of 1 mg/mL in PBS and incubated overnight at 4°C. The coated wells were blocked with PBS containing 2.5% bovine serum albumin (Sigma-Aldrich Corporation, St. Louis, MO, USA) for 2 h at 37°C. A 100 µL milk sample, which was diluted 1:200, 1:400, 1:800, and 1:1,200 with PBS containing 0.05% Tween 20 was dispensed to the microplate. Horseradish-peroxidase-conjugated goat anti-bovine IgG antibody (Southern Biotechnology Associates Inc, Birmingham, AL, USA) which was diluted 1:8,000 and tetramethylbenzidine peroxide substrate systems were used as the secondary antibody and the substrate, respectively. Absorbance at 450 nm (A450) was measured after the reaction was terminated with 1 M H2SO4. The maximal milk dilution giving an A450 of 0.5 was expressed as the antibody titer.

Disinfection of milk

The presences of antibodies were confirmed by ELISA, and the antibody titer attained a peak (1:800) by serial detection. The cow antibody-containing milk was then collected, defatted, processed into sterile milk by pasteurization, and stored at −20°C until required. Similarly, milk prepared from non-immunized cows was used as the placebo.

Clinical trial

The study protocols were approved by the Ethics Committee of Hebei Medical University Fourth Hospital according to Declaration of Helsinki criteria. All subjects were provided with a notice of written consent before enrollment. Because of the exploratory nature of this study, the sample calculation was based on previous literature of about 1–5%/year spontaneous clearance rate of H. pylori infection [34]. Based on Fisher’s exact test with a unilateral hypothesis and an expectation of an increase in the eradication rate of 30% with bovine anti-H. pylori antibodies compared with the 5%/year spontaneous clearance rate of the infection, the sample size was calculated to be 28 patients for each group of either the antibody milk or placebo group for a power of 0.80 and a significance level of 0.05. The clinical study was designed to be a randomized double-blind placebo-controlled trial. The randomization was carried out by using a list obtained by computerization. Patients received their numbers in an ascending order for enrollment. This number corresponded to the randomized regimen for the use of medication with antibody milk or placebo. None of the patients were aware of the randomization, and the investigators, who were also blinded to the randomization, followed the treatment and performed all examinations independently.

416 volunteers from Shijiazhuang city were enrolled for the trial, the volunteers population consisting of 233 men and 183 women with a mean age of 39 (age range 20–67). First, the patients infected with H. pylori were screened by detecting anti-H. pylori IgG antibody in the volunteer’s serum by using the ASSURE H. pylori Rapid Test kit (MP Biomedicals LLC, Santa Ana, CA, USA). Second, volunteers with positive serum antibodies were confirmed as being infected with H. pylori by the carbon-14-labeled urea breath test. According to the inclusion and exclusion criteria, 61 volunteers (34 males and 27 females) were enrolled in the clinical trial and randomly assigned to either the antibody milk (in total 31 subjects, 15 males and 16 females, age range 21–57, mean 36) or placebo (in total 30 subjects, 19 males and 11 females, age range 26–63, mean 42) group. Inclusion criteria were subjects who were enrolled were over 18 years old with H. pylori infection and the O blood group, with no previous treatment for the infection and no use of anti-inflammatory or antibiotic drugs within 4 weeks prior to enrollment. Exclusion criteria were subjects were excluded with lactose intolerance, pregnancy or lactation, malignancy, significant systemic comorbidity, over 80 years, a history of gastrointestinal surgery, erosive esophagitis, or use of low-dose aspirin. Patients who had undergone previous treatment for H. pylori infection with standard therapy were also excluded.

The stored cow milk was thawed and warmed at 37°C prior to use. Based on the recommended daily amount of the consumption of milk, all subjects received either 200 mL immune-milk + 1 mL NaHCO3 (1 mol/L) or placebo + 1 mL NaHCO3 (1 mol/L) once a day, 1–1.5 h after dinner for 28 days. The follow-up period was 56 days. 14C-urea breath tests were performed three times, namely at the start of the study, after completion of the study medication, and at the end of the follow-up. The questionnaires for adverse events were completed at the 7, 14, 28, and 56 days; all patients answered a questionnaire on dyspeptic symptoms and the most common symptoms related to possible adverse effects attributable to treatment (Table 2). Each symptom was quantified as –(0), +(1), ++(2), and +++(3). The questionnaire allowed the inclusion of new symptoms that were considered as adverse effects in the assessments after antibody milk administration. The number and grade of symptoms in all patients were evaluated. Previous symptoms that increased in grade during and after treatment were also considered as adverse effects.
Table 2

Symptom questionnaires

Symptom

+

++

+++

Flatulence

    

Abnormal taste

    

Diarrhea

    

Vomiting

    

Epigastric pain

    

Pirosis

    

Heartburn

    

Regurgitation

    

Postprandial fullness

    

Nausea

    

Other (discriminate)

    

Values

0

1

2

3

+++ Symptom interferes with normal activity >50% of evaluated time, ++ symptom interferes with normal activity <50% of evaluated time, + symptom does not interfere with normal activity, – without symptoms.

Data analysis

A statistical analysis was performed by using SPSS 17.0 software for Windows. The Pearson Chi Square test was used to compare variables for clearance and adverse effect incidence, and a two-sided P < 0.05 was considered statistically significant. The grades of adverse events at 7, 14, 28, and 56 days were evaluated by the Mann–Whitney test by using the value obtained from the symptom questionnaire.

Results

One volunteer in the antibody group and 2 volunteers in the control group dropped out of the trial because they had moved out of the region; 58 subjects completed the study with 30 in the antibody group and 28 in the placebo group (Figures 1, 2). The clearance efficacy of the antibody milk was evaluated according to the results of the 14C-urea breath tests; 13 of 30 antibody-treated subjects became UBT negative, whereas none of the 30 placebo-treated subjects became UBT negative after completion of the study medication; 3 of the 13 UBT-negative subjects became positive at the end of the follow-up. The per-protocol (PP) and intention to treat (ITT) with antibody milk and with placebo both indicated a significant difference in the clearance rate of infected patients between the bovine milk containing antibodies and the placebo-treated group (P = 0.001, P < 0.05). No significant differences were seen in the score of adverse effect in the antibody group compared with the placebo group on 7, 14, 28, and 56 days (P > 0.05 for all).
Figure 1

Patient flow in the pilot study with bovine anti-Helicobacter pylori antibodies in milk.

Figure 2

Consort diagram. ITT intention to treat, PP per protocol.

Safety

None of the patients experienced adverse effects attributable to the antibody milk treatment, and the antibody milk was well tolerated.

Discussion

The previous in vitro studies have demonstrated the good effects of treatment with bovine antibody-containing milk, but the in vivo clinical studies that are available have shown no H. pylori eradication [2229, 35, 36]. More studies on a variety of factors such as the optimal length of treatment, the optimal antibody dose, adjunctive acid suppression, are needed to solve the discrepancy of outcome between the in vitro and in vivo investigations.

Helicobacter pylori inhabits the 100 µm-thick mucus layer, particularly the 25 µm close to the gastric epithelial cells [37]. Previous literature has shown that pH influences the extent of binding of H. pylori-specific antibodies in the milk to H. pylori, with no binding being observed under pH 4.0 and maximum binding at pH 7–8 [38]. Thus, NaHCO3 has to be added to the milk so that the elevation in mucus pH can decrease the viscosity of the mucus and contribute to the penetration of antibodies into the mucus.

The main problems with the use of antibodies to prevent and control infectious diseases are the variability of the antigen. The genotype and serotype of H. pylori of different regions varies significantly from country to country, and even between regions within the same country [39, 40]. Previous studies have indicated that the H. pylori-specific antibodies bind to different clinically isolated H. pylori stains with less than a tenfold variation in titer [38]. Our clinical trial has shown a positive effect and safety in O blood group H. pylori-infected subpopulations following the oral administration of polyclonal antibodies in defatted milk, in which casein has not been discarded considering that casein can elevate mucus pH. However, to date, an effective treatment of the H. pylori infection has proven difficult, considering costs, adverse effects, and the increasing emergence of antibiotic-resistant strains [12, 13, 15, 41, 42]. The use of anti-H. pylori bovine antibodies in milk to control the H. pylori infection has many advantages such as low costs, nutrients, and good compliance, without the development of antibiotic resistance in H. pylori or other flora and the tolerance of long-term use. Many factors might influence the clinical effect, including the different pH microenvironments between patients, the antibodies titers in the milk, high gastric acidity, a high bacterial load, persistent infection, bacterial self-protecting mechanisms (such as the flagella of H. pylori, which are covered by a flagellar sheath and therefore are thought to be shielded from antibody selection), the different blood types of patients, the genotype deference between immunized and infected bacteria, the optimal length and dose of treatment, the oral administration time, and the size of the study population. However, the degree of match between the immunization and the patient infection strains might be the crucial in influencing the effect of the clinical trial. Therefore, we have selected the locally prevalent H. pylori stains to immunize the dairy cows. H. pylori possesses an enormous genomic diversity and plasticity that facilitate host adaptation. Simultaneously, many studies have suggested that H. pylori has a much higher recombination rate and mutation than most other microorganisms [43]. Variable expression of fucosyltransferases enables H. pylori strains to alter their host-recognizable antigens by mimicking human Lewis antigens in order to evade their host’s immune response [9, 44]. Genetic diversification of the H. pylori adhesin genes might allow the adaptation of adherence properties to better facilitate persistence, despite host defenses. The different genotypes of H. pylori have their respective phenotypes with regard to cell envelope and surface structure, especially their adhesins [45]. Different adhesins bind different antigens [46, 47]. For example, adhesins SabB and SabA bind sialic acid, and adhesin BabB binds Lewis b antigen [47, 48]. Frequent H. pylori infection in crowded living conditions and the clustering of the cases occurring within family units indicate that different regions have different locally prevalent strains. The local prevalent H. pylori strains must therefore be selected to immunize the dairy cows. However, the overall efficacy of the 33.3% (10/30) clearance rate in our study is low and is not suitable clinically for the treatment of H. pylori infection. This might be because the selected immunization strain was not the actual locally prevalent strain in our study because we screened a single vacA gene locus. More gene loci such as the genes of the flagellum and adhesins need to be screened.

Breast-feeding during the first months after birth decreases human infant morbidity and mortality from diarrheal and systemic infection because the colostrum conveys protection to the immunologically naïve infant against a variety of microbial pathogens by immunoglobulins [49]. Whole bovine immune-milk mimics natural protection in humans and has been used in infants for the treatment or prevention of enteric infections by bacterial, viral, and protozoal pathogens. H. pylori expresses adhesins of BabA/B, SabA, AlpA/B, OipA, and HopZ, which confer intimate adherence to the gastric epithelium, whereby the bacteria can gain easy access to nutrients from host tissues [10, 11, 37, 46, 48]. Antibodies against BabA/B, SabA/B, AlpA/B, OipA, HopZ, and urease can disrupt the ability of H. pylori to colonize the gastric mucosa and limit its ability to garner essential nutrients. Our study might have been limited by the fact that we did not ascertain whether milk taken from immunized cows contained the specific antibodies mentioned above. Therefore, future research is necessary to ascertain the type of antibodies described above.

At the end of the follow-up, 3 of the 13 UBT-negative patients relapsed partly because of the existence of bacteria in the intercellular junctions or the intracellular submucosa which the bovine antibodies were unable to reach in sufficient concentrations to block the bacteria. Recent studies have indicated that the oral cavity is not only a potential reservoir for H. pylori infection of the stomach, but also a potential reservoir for re-infection. Previous studies have indicated that patients with oral H. pylori are at a significantly greater risk of gastric reinfection following successful therapy [50, 51]. Another explanation is that mixed infections by two or more strains are common in China [52].

Conclusions

Although the bovine antibody-based oral immunotherapy demonstrated good effects on controlling the H. pylori infection in our study, it cannot fully replace the therapeutic strategies with antibiotics, because of the small size of the investigated population. Further studies on larger populations and the relationships between the genetic diversity and pathogenicity of H. pylori strains, an analysis of the volunteers’ H. pylori genotype and phenotype, and the selection of the actual locally prevalent H. pylori stains will be required before this particular novel and potentially therapeutic strategy for the eradication of this microorganism can be fully developed.

Abbreviations

cagA: 

cytotoxin associated gene A

vacA: 

vacuolating cytotoxin A

BabA/B: 

blood group antigen-binding adhesion A/B

SabA/B: 

sialic acid-binding adhesion A/B

HopZ: 

Helicobacter outer membrane porins Z

AlpA/B: 

adherence-associated lipoprotein A/B

OipA: 

outer inflammatory protein A

Declarations

Authors’ contributions

Conceived and planned the whole study and revised the manuscript: ZS CZ. Cultured and prepared the locally prevalent H. pylori as a vaccine for immunization and primarily responsible for writing the manuscript: DH. Provided the dairy cows for immunization and managed and fed the cows: FZ. Collected and disinfected the milk: JZ. Immunized dairy cows: BX. Took care of the patients involved, questioned the patients and recorded any adverse effects mentioned by them: HZ. Responsible for detection of anti-H. pylori-specific antibodies in milk by ELSA: HQ. Statistical analysis of data: SR. Recruited and screened volunteers: BS. Design of the randomized double-blind clinical trial: CY. Transported the milk: ZZ. Responsible for carbon-14-labeled urea breath test: XW. All authors read and approved the final manuscript.

Acknowledgements

The authors are grateful to the help of Bin Ma, Bu-Lang Gao, Hai-Lin Zhang and Ting-Gui Wang.

Funding

This work was supported by Hebei Health Department Foundation (Grant number: GL2012049).

Compliance with ethical guidelines

Competing interests The authors declare that they have no competing interests.

Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Authors’ Affiliations

(1)
Clinical Department, The Research Section of Experimentation Teaching Center, Hebei Medical University
(2)
Shijiazhuang Center for Disease Control and Prevention
(3)
The Institute of Cereal and Oil Crop, Hebei Academy of Agriculture and Forestry Sciences
(4)
The Fourth Hospital of Hebei Medical University
(5)
Shijiazhuang Center for Prevention and Control of Animal Diseases

References

  1. Marshall BJ, Warren JR (1984) Unidentified curved bacilli in the stomach of patients with gastritis and peptic ulceration. Lancet 1:1311–1315PubMedView ArticleGoogle Scholar
  2. Moller H, Heseltine E, Vainio H (1995) Working group report on schistosomes, liver flukes and Helicobacter pylori. Int J Cancer 60:587–589PubMedView ArticleGoogle Scholar
  3. Panayotopoulou EG, Sgouras DN, Papadakos KS, Petraki K, Breurec S, Michopoulos S et al (2010) CagA and VacA polymorphisms are associated with distinct pathological features in Helicobacter pylori-infected adults with peptic ulcer and non-peptic ulcer disease. J Clin Microbiol 48:2237–2239PubMed CentralPubMedView ArticleGoogle Scholar
  4. Duncan SS, Valk PL, Shaffer CL, Bordenstein SR, Cover TL (2012) J-Western forms of Helicobacter pylori cagA constitute a distinct phylogenetic group with a widespread geographic distribution. J Bacteriol 194:1593–1604PubMed CentralPubMedView ArticleGoogle Scholar
  5. Yamaoka Y, Kato M, Asaka M (2008) Geographic differences in gastric cancer incidence can be explained by differences between Helicobacter pylori strains. Intern Med 47:1077–1083PubMed CentralPubMedView ArticleGoogle Scholar
  6. van Doorn LJ, Figueiredo C, Sanna R, Pena S, Midolo P, Ng EK et al (1998) Expanding allelic diversity of Helicobacter pylori vacA. J Clin Microbiol 36:2597–2603PubMed CentralPubMedGoogle Scholar
  7. Saribasak H, Salih BA, Yamaoka Y, Sander E (2004) Analysis of Helicobacter pylori genotypes and correlation with clinical outcome in Turkey. J Clin Microbiol 42:1648–1651PubMed CentralPubMedView ArticleGoogle Scholar
  8. Britton S, Papp-Szabo E, Simala-Grant J, Morrison L, Taylor DE, Monteiro MA (2005) A novel Helicobacter pylori cell-surface polysaccharide. Carbohydr Res 340:1605–1611PubMedView ArticleGoogle Scholar
  9. Monteiro MA, Chan KH, Rasko DA, Taylor DE, Zheng PY, Appelmelk BJ et al (1998) Simultaneous expression of type 1 and type 2 Lewis blood group antigens by Helicobacter pylori lipopolysaccharides. Molecular mimicry between H. pylori lipopolysaccharides and human gastric epithelial cell surface glycoforms. J Biol Chem 273:11533–11543PubMedView ArticleGoogle Scholar
  10. Magalhaes A, Reis CA (2010) Helicobacter pylori adhesion to gastric epithelial cells is mediated by glycan receptors. Braz J Med Biol Res 43:611–618PubMedView ArticleGoogle Scholar
  11. Aspholm-Hurtig M, Dailide G, Lahmann M, Kalia A, Ilver D, Roche N et al (2004) Functional adaptation of BabA, the H. pylori ABO blood group antigen binding adhesin. Science 305:519–522PubMedView ArticleGoogle Scholar
  12. Urgesi R, Cianci R, Riccioni ME (2012) Update on triple therapy for eradication of Helicobacter pylori: current status of the art. Clin Exp Gastroenterol 5:151–157PubMed CentralPubMedView ArticleGoogle Scholar
  13. Zullo A, Hassan C, Ridola L, De Francesco V, Vaira D (2013) Standard triple and sequential therapies for Helicobacter pylori eradication: an update. Eur J Intern Med 24:16–19PubMedView ArticleGoogle Scholar
  14. Kim JS, Park SM, Kim BW (2015) Sequential or concomitant therapy for eradication of H. pylori infection: a systematic review and meta-analysis. J Gastroenterol Hepatol. doi:10.1111/jgh.12984 Google Scholar
  15. Xie C, Lu NH (2015) Review: clinical management of Helicobacter pylori infection in China. Helicobacter 20:1–10PubMedView ArticleGoogle Scholar
  16. Opekun AR, El-Zaimaity HM, Osato MS, Gilger MA, Malaty HM, Terry M et al (1999) Novel therapies for Helicobacter pylori infection. Aliment Pharm Ther 13:35–42View ArticleGoogle Scholar
  17. Davidson GP, Whyte PB, Daniels E, Franklin K, Nunan H, McCloud PI et al (1989) Passive immunisation of children with bovine colostrum containing antibodies to human rotavirus. Lancet 2:709–712PubMedView ArticleGoogle Scholar
  18. Ruiz-Palacios GM, Calva JJ, Pickering LK, Lopez-Vidal Y, Volkow P, Pezzarossi H et al (1990) Protection of breast-fed infants against Campylobacter diarrhea by antibodies in human milk. J Pediatr 116:707–713PubMedView ArticleGoogle Scholar
  19. Tollemar J, Gross N, Dolgiras N, Jarstrand C, Ringden O, Hammarstrom L (1999) Fungal prophylaxis by reduction of fungal colonization by oral administration of bovine anti-Candida antibodies in bone marrow transplant recipients. Bone Marrow Transpl 23:283–290View ArticleGoogle Scholar
  20. Torres O, Cruz JR (1993) Protection against Campylobacter diarrhea: role of milk IgA antibodies against bacterial surface antigens. Acta Paediatr 82:835–838PubMedGoogle Scholar
  21. van Dissel JT, de Groot N, Hensgens CM, Numan S, Kuijper EJ, Veldkamp P et al (2005) Bovine antibody-enriched whey to aid in the prevention of a relapse of Clostridium difficile-associated diarrhoea: preclinical and preliminary clinical data. J Med Microbiol 54:197–205PubMedView ArticleGoogle Scholar
  22. Attallah AM, Abbas AT, Ismail H, Abdel-Raouf M, El-Dosoky I (2009) Efficacy of passive immunization with IgY antibodies to a 58-kDa H. pylori antigen on severe gastritis in BALB/c mouse model. J Immunoass Immunochem 30:359–377View ArticleGoogle Scholar
  23. Czinn SJ, Cai A, Nedrud JG (1993) Protection of germ-free mice from infection by Helicobacter felis after active oral or passive IgA immunization. Vaccine 11:637–642PubMedView ArticleGoogle Scholar
  24. Gorrell RJ, Robins-Browne RM (2009) Antibody-mediated protection against infection with Helicobacter pylori in a suckling mouse model of passive immunity. Infect Immun 77:5116–5129PubMed CentralPubMedView ArticleGoogle Scholar
  25. Marnila P, Rokka S, Rehnberg-Laiho L, Karkkainen P, Kosunen TU, Rautelin H et al (2003) Prevention and suppression of Helicobacter felis infection in mice using colostral preparation with specific antibodies. Helicobacter 8:192–201PubMedView ArticleGoogle Scholar
  26. Casswall TH, Nilsson HO, Bjorck L, Sjostedt S, Xu L, Nord CK et al (2002) Bovine anti-Helicobacter pylori antibodies for oral immunotherapy. Scand J Gastroenterol 37:1380–1385PubMedView ArticleGoogle Scholar
  27. Casswall TH, Sarker SA, Albert MJ, Fuchs GJ, Bergstrom M, Bjorck L et al (1998) Treatment of Helicobacter pylori infection in infants in rural Bangladesh with oral immunoglobulins from hyperimmune bovine colostrum. Aliment Pharm Ther 12:563–568View ArticleGoogle Scholar
  28. den Hoed CM, de Vries AC, Mensink PB, Dierikx CM, Suzuki H, Capelle L et al (2011) Bovine antibody-based oral immunotherapy for reduction of intragastric Helicobacter pylori colonization: a randomized clinical trial. Can J Gastroenterol 25:207–213Google Scholar
  29. Suzuki H, Nomura S, Masaoka T, Goshima H, Kamata N, Kodama Y et al (2004) Effect of dietary anti-Helicobacter pylori-urease immunoglobulin Y on Helicobacter pylori infection. Aliment Pharm Ther 20(Suppl 1):185–192View ArticleGoogle Scholar
  30. Arevalo-Galvis A, Trespalacios-Rangell AA, Otero W, Mercado-Reyes MM, Poutou-Pinales RA (2012) Prevalence of cagA, vacA, babA2 and iceA genes in H. pylori strains isolated from Colombian patients with functional dyspepsia. Pol J Microbiol 61:33–40PubMedGoogle Scholar
  31. Yahaghi E, Khamesipour F, Mashayekhi F, Safarpoor Dehkordi F, Sakhaei MH, Masoudimanesh M et al (2014) Helicobacter pylori in vegetables and salads: genotyping and antimicrobial resistance properties. Biomed Res Int 2014:757941PubMed CentralPubMedView ArticleGoogle Scholar
  32. Wirth HP, Yang M, Karita M, Blaser MJ (1996) Expression of the human cell surface glycoconjugates Lewis x and Lewis y by Helicobacter pylori isolates is related to cagA status. Infect Immun 64:4598–4605PubMed CentralPubMedGoogle Scholar
  33. Simoons-Smit IM, Appelmelk BJ, Verboom T, Negrini R, Penner JL, Aspinall GO et al (1996) Typing of Helicobacter pylori with monoclonal antibodies against Lewis antigens in lipopolysaccharide. J Clin Microbiol 34:2196–2200PubMed CentralPubMedGoogle Scholar
  34. Luzza F, Suraci E, Larussa T, Leone I, Imeneo M (2014) High exposure, spontaneous clearance, and low incidence of active Helicobacter pylori infection: the Sorbo San Basile study. Helicobacter 19:296–305PubMedView ArticleGoogle Scholar
  35. Wang B, Yang J, Cao S, Wang H, Pan X, Zhu J et al (2014) Preparation of specific anti-Helicobacter pylori yolk antibodies and their antibacterial effects. Int J Clin Exp Pathol 7:6430–6437PubMed CentralPubMedGoogle Scholar
  36. Bitzan MM, Gold BD, Philpott DJ, Huesca M, Sherman PM, Karch H et al (1998) Inhibition of Helicobacter pylori and Helicobacter mustelae binding to lipid receptors by bovine colostrum. J Infect Dis 177:955–961PubMedView ArticleGoogle Scholar
  37. Moore ME, Boren T, Solnick JV (2011) Life at the margins: modulation of attachment proteins in Helicobacter pylori. Gut Microbes 2:42–46PubMed CentralPubMedView ArticleGoogle Scholar
  38. Early EM, Hardy H, Forde T, Kane M (2001) Bactericidal effect of a whey protein concentrate with anti-Helicobacter pylori activity. J App Microbiol 90:741–748View ArticleGoogle Scholar
  39. Chung C, Olivares A, Torres E, Yilmaz O, Cohen H, Perez-Perez G (2010) Diversity of VacA intermediate region among Helicobacter pylori strains from several regions of the world. J Clin Microbiol 48:690–696PubMed CentralPubMedView ArticleGoogle Scholar
  40. Dabiri H, Maleknejad P, Yamaoka Y, Feizabadi MM, Jafari F, Rezadehbashi M et al (2009) Distribution of Helicobacter pylori cagA, cagE, oipA and vacA in different major ethnic groups in Tehran, Iran. J Gastroenterol Hepatol 24:1380–1386PubMed CentralPubMedView ArticleGoogle Scholar
  41. Gatta L, Vakil N, Vaira D, Scarpignato C (2013) Global eradication rates for Helicobacter pylori infection: systematic review and meta-analysis of sequential therapy. BMJ 347:f4587PubMed CentralPubMedView ArticleGoogle Scholar
  42. Talebi Bezmin Abadi A (2014) Therapy of Helicobacter pylori: present medley and future prospective. Biomed Res Int. doi:10.1155/2014/124607 PubMed CentralPubMedGoogle Scholar
  43. Linz B, Schuster SC (2007) Genomic diversity in Helicobacter and related organisms. Res Microbiol 158:737–744PubMedView ArticleGoogle Scholar
  44. Nilsson C, Skoglund A, Moran AP, Annuk H, Engstrand L, Normark S (2008) Lipopolysaccharide diversity evolving in Helicobacter pylori communities through genetic modifications in fucosyltransferases. PLoS One 3:e3811PubMed CentralPubMedView ArticleGoogle Scholar
  45. Tomb JF, White O, Kerlavage AR, Clayton RA, Sutton GG, Fleischmann RD et al (1997) The complete genome sequence of the gastric pathogen Helicobacter pylori. Nature 388:539–547PubMedView ArticleGoogle Scholar
  46. Pride DT, Meinersmann RJ, Blaser MJ (2001) Allelic Variation within Helicobacter pylori babA and babB. Infect Immun 69:1160–1171PubMed CentralPubMedView ArticleGoogle Scholar
  47. Odenbreit S, Faller G, Haas R (2002) Role of the alpAB proteins and lipopolysaccharide in adhesion of Helicobacter pylori to human gastric tissue. Int J Med Microbiol 292:247–256PubMedView ArticleGoogle Scholar
  48. Oleastro M, Menard A (2013) The Role of Helicobacter pylori outer membrane proteins in adherence and pathogenesis. Biology 2:1110–1134PubMed CentralPubMedView ArticleGoogle Scholar
  49. Thomas JE, Austin S, Dale A, McClean P, Harding M, Coward WA et al (1993) Protection by human milk IgA against Helicobacter pylori infection in infancy. Lancet 342:121PubMedView ArticleGoogle Scholar
  50. Amiri N, Abiri R, Eyvazi M, Zolfaghari MR, Alvandi A (2015) The frequency of Helicobacter pylori in dental plaque is possibly underestimated. Arch Oral Biol 60:782–788PubMedView ArticleGoogle Scholar
  51. Czesnikiewicz-Guzik M, Karczewska E, Bielanski W, Guzik TJ, Kapera P, Targosz A et al (2004) Association of the presence of Helicobacter pylori in the oral cavity and in the stomach. J Physiol Pharmacol 55(Suppl 2):105–115PubMedGoogle Scholar
  52. Ghose C, Perez-Perez GI, van Doorn LJ, Dominguez-Bello MG, Blaser MJ (2005) High frequency of gastric colonization with multiple Helicobacter pylori strains in Venezuelan subjects. J Clin Microbiol 43:2635–2641PubMed CentralPubMedView ArticleGoogle Scholar

Copyright

© Hu et al. 2015

Advertisement